Literature DB >> 26393374

Improving the Selectivity of Engineered Protease Inhibitors: Optimizing the P2 Prime Residue Using a Versatile Cyclic Peptide Library.

Simon J de Veer1, Conan K Wang2, Jonathan M Harris1, David J Craik2, Joakim E Swedberg2.   

Abstract

Standard mechanism inhibitors are attractive design templates for engineering reversible serine protease inhibitors. When optimizing interactions between the inhibitor and target protease, many studies focus on the nonprimed segment of the inhibitor's binding loop (encompassing the contact β-strand). However, there are currently few methods for screening residues on the primed segment. Here, we designed a synthetic inhibitor library (based on sunflower trypsin inhibitor-1) for characterizing the P2' specificity of various serine proteases. Screening the library against 13 different proteases revealed unique P2' preferences for trypsin, chymotrypsin, matriptase, plasmin, thrombin, four kallikrein-related peptidases, and several clotting factors. Using this information to modify existing engineered inhibitors yielded new variants that showed considerably improved selectivity, reaching up to 7000-fold selectivity over certain off-target proteases. Our study demonstrates the importance of the P2' residue in standard mechanism inhibition and unveils a new approach for screening P2' substitutions that will benefit future inhibitor engineering studies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26393374     DOI: 10.1021/acs.jmedchem.5b01148

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  15 in total

1.  Iterative Optimization of the Cyclic Peptide SFTI-1 Yields Potent Inhibitors of Neutrophil Proteinase 3.

Authors:  Sixin Tian; Joakim E Swedberg; Choi Yi Li; David J Craik; Simon J de Veer
Journal:  ACS Med Chem Lett       Date:  2019-07-19       Impact factor: 4.345

2.  S2'-subsite variations between human and mouse enzymes (plasmin, factor XIa, kallikrein) elucidate inhibition differences by tissue factor pathway inhibitor -2 domain1-wild-type, Leu17Arg-mutant and aprotinin.

Authors:  K Vadivel; Y Kumar; G I Ogueli; S M Ponnuraj; P Wongkongkathep; J A Loo; M S Bajaj; S P Bajaj
Journal:  J Thromb Haemost       Date:  2016-11-19       Impact factor: 5.824

Review 3.  Digestive Inflammation: Role of Proteolytic Dysregulation.

Authors:  Vincent Mariaule; Aicha Kriaa; Souha Soussou; Soufien Rhimi; Houda Boudaya; Juan Hernandez; Emmanuelle Maguin; Adam Lesner; Moez Rhimi
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

4.  A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering.

Authors:  Amiram Sananes; Itay Cohen; Anat Shahar; Alexandra Hockla; Elena De Vita; Aubry K Miller; Evette S Radisky; Niv Papo
Journal:  J Biol Chem       Date:  2018-06-22       Impact factor: 5.157

5.  Linking inhibitor motions to proteolytic stability of sunflower trypsin inhibitor-1.

Authors:  Wanqing Wei; Jing Ma; Daiqian Xie; Yanzi Zhou
Journal:  RSC Adv       Date:  2019-05-03       Impact factor: 4.036

6.  Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold - A Potential Therapeutic Intervention for Skin Diseases.

Authors:  Wenjie Chen; Veronica A Kinsler; Derek Macmillan; Wei-Li Di
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

7.  Co-Expression of a Chimeric Protease Inhibitor Secreted by a Tumor-Targeted Salmonella Protects Therapeutic Proteins from Proteolytic Degradation.

Authors:  David Quintero; Jamie Carrafa; Lena Vincent; Hee Jong Lee; James Wohlschlegel; David Bermudes
Journal:  J Microbiol Biotechnol       Date:  2018-12-28       Impact factor: 3.277

8.  An unexpected switch in peptide binding mode: from simulation to substrate specificity.

Authors:  Ursula Kahler; Julian E Fuchs; Peter Goettig; Klaus R Liedl
Journal:  J Biomol Struct Dyn       Date:  2018-01-31

9.  Potent, multi-target serine protease inhibition achieved by a simplified β-sheet motif.

Authors:  Xingchen Chen; Blake T Riley; Simon J de Veer; David E Hoke; Jessica Van Haeften; Darren Leahy; Joakim E Swedberg; Maria Brattsand; Perry J Hartfield; Ashley M Buckle; Jonathan M Harris
Journal:  PLoS One       Date:  2019-01-22       Impact factor: 3.240

10.  Enhanced Antifibrinolytic Efficacy of a Plasmin-Specific Kunitz-Inhibitor (60-Residue Y11T/L17R with C-Terminal IEK) of Human Tissue Factor Pathway Inhibitor Type-2 Domain1.

Authors:  Kanagasabai Vadivel; Anne K Zaiss; Yogesh Kumar; Frank M Fabian; Ayman E A Ismail; Mark A Arbing; Wallace G Buchholz; William H Velander; S Paul Bajaj
Journal:  J Clin Med       Date:  2020-11-17       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.